GSK Signs a Research Collaboration with Clover for the Evaluation of Coronavirus (COVID-19) Vaccine

 GSK Signs a Research Collaboration with Clover for the Evaluation of Coronavirus (COVID-19) Vaccine

GSK’s Nucala (mepolizumab) Receives European Commission Approval for Self-Administration in Severe Eosinophilic Asthma

Shots:

  • GSK to provide pandemic adjuvant system to Clover to evaluate S-Trimer in preclinical studies while Clover has largest commercial-scale cGMP biomanufacturing capabilities in China involved in rapid scale-up and produce new coronavirus vaccine
  • The focus of the collaboration is to evaluate the combination of GSK’s pandemic adjuvant system with Clover’s S-Trimer as a vaccine candidate utilizing its own Timer-Tag technology to develop vaccines for corona virus
  • Trimer-Tag technology is a drug development platform involved in production of novel covalently-trimerized fusion proteins targeted to these previously undruggable pathways

Click here to read full press release/ article | Ref: GSK | Image: Twitter

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post